These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 10699903

  • 1. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.
    Yan Y, Carvalhal GF, Catalona WJ, Young JD.
    Cancer; 2000 Mar 01; 88(5):1122-30. PubMed ID: 10699903
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 5. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA.
    Cancer; 2002 Dec 01; 95(11):2302-7. PubMed ID: 12436435
    [Abstract] [Full Text] [Related]

  • 6. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S.
    Contemp Clin Trials; 2009 Jan 01; 30(1):81-7. PubMed ID: 18783735
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 9. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC.
    Cancer; 2003 Dec 01; 98(11):2344-50. PubMed ID: 14635068
    [Abstract] [Full Text] [Related]

  • 10. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schröder FH.
    Eur Urol; 2006 Sep 01; 50(3):475-82. PubMed ID: 16713065
    [Abstract] [Full Text] [Related]

  • 11. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S.
    BJU Int; 2006 Sep 01; 98(3):549-53. PubMed ID: 16925752
    [Abstract] [Full Text] [Related]

  • 12. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Mol Urol; 2000 Sep 01; 4(3):171-5;discussion 177. PubMed ID: 11062371
    [Abstract] [Full Text] [Related]

  • 13. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 14. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV.
    Urology; 2007 Mar 01; 69(3):515-9. PubMed ID: 17382156
    [Abstract] [Full Text] [Related]

  • 15. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
    Potters L, Purrazzella R, Brustein S, Fearn P, Leibel SA, Kattan MW.
    Cancer; 2002 Oct 01; 95(7):1451-6. PubMed ID: 12237913
    [Abstract] [Full Text] [Related]

  • 16. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D.
    BJU Int; 2005 May 01; 95(7):956-60. PubMed ID: 15839912
    [Abstract] [Full Text] [Related]

  • 17. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
    Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR.
    J Urol; 2003 Nov 01; 170(5):1804-7. PubMed ID: 14532780
    [Abstract] [Full Text] [Related]

  • 18. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.
    J Urol; 2001 Dec 01; 166(6):2193-7. PubMed ID: 11696734
    [Abstract] [Full Text] [Related]

  • 19. Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
    Krygiel JM, Smith DS, Homan SM, Sumner W, Nease RF, Brownson RC, Catalona WJ.
    J Urol; 2005 Jul 01; 174(1):126-30. PubMed ID: 15947596
    [Abstract] [Full Text] [Related]

  • 20. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
    Shimizu F, Igarashi A, Fukuda T, Kawachi Y, Minowada S, Ohashi Y, Fujime M.
    Jpn J Clin Oncol; 2007 Oct 01; 37(10):763-74. PubMed ID: 17956899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.